Status:
COMPLETED
Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers
Lead Sponsor:
University of Rostock
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Smoke-related Lung Diseases
Chronic Obstructive Pulmonary Disease
Eligibility:
MALE
30-60 years
Phase:
PHASE1
Brief Summary
Airway dendritic cells (DCs) play a key role in smoke-related lung diseases. In this study, the researchers investigate the effects of fluticasone and salmeterol on human airway DCs in smokers. The re...
Eligibility Criteria
Inclusion
- Men aged 30 - 60 years
- At least 15 years of smoking
- Current smoker, at least 10 cigarettes per day
Exclusion
- Any acute or chronic disease (except COPD oder hypertension)
- Any regular medication (except drugs against hypertension)
- FEV1 \< 80% predicted
- Oxygen saturation \< 90%
- Acute infections of the lower respiratory tract in the last 7 days before the first day of the study
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00908362
Start Date
May 1 2009
End Date
December 1 2009
Last Update
January 13 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dep. of Pneumology, University of Rostock
Rostock, Mecklenburg-Vorpommern, Germany, 18057